
Adults with serious mental illness receive GLP-1 prescriptions at rates similar to or higher than their peers, though schizophrenia continued to lag.
CMS' ruling that Aranesp and Procrit are functionally equivalent so they should get the same reimbursement is creating a stir among drug companies which feel that one product has more advantages than the other and should deserve more payment.






